Persistently hyperphosphorylated Akt contributes to human oncogenesis and resistance to therapy. Triciribine (TCN) phosphate (TCN-P), the active metabolite of the Akt phosphorylation inhibitor TCN, is in clinical trials, but the mechanism by which TCN-P inhibits Akt phosphorylation is unknown. Here we show that in vitro, TCN-P inhibits neither Akt activity nor the phosphorylation of Akt S473 and T308 by mammalian target of rapamycin or phosphoinositide-dependent kinase 1. However, in intact cells, TCN inhibits EGF-stimulated Akt recruitment to the plasma membrane and phosphorylation of Akt. Surface plasmon resonance shows that TCN, but not TCN, binds Akt-derived pleckstrin homology (PH) domain (K D : 690 nM). Furthermore, nuclear magnetic resonance spectroscopy shows that TCN-P, but not TCN, binds to the PH domain in the vicinity of the PIP3-binding pocket. Finally, constitutively active Akt mutants, Akt1-T308D/S473D and myr-Akt1, but not the transforming mutant Akt1-E17K, are resistant to TCN and rescue from its inhibition of proliferation and induction of apoptosis. Thus, the results of our studies indicate that TCN-P binds to the PH domain of Akt and blocks its recruitment to the membrane, and that the subsequent inhibition of Akt phosphorylation contributes to TCN-P antiproliferative and proapoptotic activities, suggesting that this drug may be beneficial to patients whose tumors express persistently phosphorylated Akt. The Ser/Thr-specific protein kinase Akt was discovered in 1991 1-3 and has since emerged as an important promoter of tumor cell survival, proliferation as well as migration and invasion. 4, 5 In mammals, Akt is represented by three isoforms, which share 74% amino acid sequence identity. Despite this high degree of homology, Akt isoforms may have distinct roles in development and normal physiology. For example, targeted gene deletions in mice have shown that loss of Akt1 function results in smaller body size and significant growth defects. 6, 7 Mice lacking Akt2 are unable to maintain glucose homeostasis and are diabetic, 8 whereas Akt3 knockout mice have smaller brains but are otherwise normal.
Persistently hyperphosphorylated Akt contributes to human oncogenesis and resistance to therapy. Triciribine (TCN) phosphate (TCN-P), the active metabolite of the Akt phosphorylation inhibitor TCN, is in clinical trials, but the mechanism by which TCN-P inhibits Akt phosphorylation is unknown. Here we show that in vitro, TCN-P inhibits neither Akt activity nor the phosphorylation of Akt S473 and T308 by mammalian target of rapamycin or phosphoinositide-dependent kinase 1. However, in intact cells, TCN inhibits EGF-stimulated Akt recruitment to the plasma membrane and phosphorylation of Akt. Surface plasmon resonance shows that TCN, but not TCN, binds Akt-derived pleckstrin homology (PH) domain (K D : 690 nM). Furthermore, nuclear magnetic resonance spectroscopy shows that TCN-P, but not TCN, binds to the PH domain in the vicinity of the PIP3-binding pocket. Finally, constitutively active Akt mutants, Akt1-T308D/S473D and myr-Akt1, but not the transforming mutant Akt1-E17K, are resistant to TCN and rescue from its inhibition of proliferation and induction of apoptosis. Thus, the results of our studies indicate that TCN-P binds to the PH domain of Akt and blocks its recruitment to the membrane, and that the subsequent inhibition of Akt phosphorylation contributes to TCN-P antiproliferative and proapoptotic activities, suggesting that this drug may be beneficial to patients whose tumors express persistently phosphorylated Akt. The Ser/Thr-specific protein kinase Akt was discovered in 1991 [1] [2] [3] and has since emerged as an important promoter of tumor cell survival, proliferation as well as migration and invasion. 4, 5 In mammals, Akt is represented by three isoforms, which share 74% amino acid sequence identity. Despite this high degree of homology, Akt isoforms may have distinct roles in development and normal physiology. For example, targeted gene deletions in mice have shown that loss of Akt1 function results in smaller body size and significant growth defects. 6, 7 Mice lacking Akt2 are unable to maintain glucose homeostasis and are diabetic, 8 whereas Akt3 knockout mice have smaller brains but are otherwise normal. 9 For activity, Akt requires recruitment to the plasma membrane and subsequent phosphorylation at two critical sites, T308 and S473. These events are initiated by growth factors binding to their receptors, which activate phosphatidylinositol-3 kinase (PI3K) to convert phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 recruits pleckstrin homology (PH) domain-containing proteins such as Akt to the plasma membrane, where it is phosphorylated at T308 by phosphoinositide-dependent kinase 1 (PDK1). 10 To be fully active, Akt also needs to be phosphorylated at S473. This site is phosphorylated by several kinases including DNA-dependent protein kinase (DNA-PK) 11, 12 and mammalian target of rapamycin (mTOR) complex 2 (mTORC2). 13 Whereas mTORC2-mediated phosphorylation of S473 occurs at the membrane in response to growth factors, 13 DNA-PK phosphorylates S473 in the nucleus in response to DNA damage. 11, 12 Whether phosphorylation at T308 and S473 in vivo occurs in a specific order is still controversial, 5 but in vitro, T308 and S473 can be phosphorylated independently.
14 Whereas the tumor suppressor phosphatase and tensin homologue (PTEN) antagonizes Akt signaling by dephosphorylating phosphoinositides, thereby preventing the activation of PDK1 and Akt, the mechanisms that directly terminate Akt signaling are not well characterized. pT308 is probably dephosphorylated by PP2A 15 and pS473 dephosphorylation may involve PP1 16 and/or novel PP2C-like phosphatases termed PHLPP1 and 2. 17 The PI3K/PTEN/Akt pathway is very frequently deregulated in human cancer, leading to persistent hyperphosphorylationhyperactivation of Akt. This can be due to persistent activation of receptor tyrosine kinases, activating mutations in PI3K, inactivating mutations or deletion of PTEN, 18, 19 overexpression of Akt 20, 21 or a transforming and rare Akt mutation (E17K). 22 Nonetheless, the specific roles of Akt isoforms in tumorigenesis are poorly understood. For instance, Akt1 is persistently activated in many cancers, and loss of Akt1 expression by antisense oligonucleotides results in inhibition of anchorageindependent growth and induction of apoptosis. 23 Overexpression of Akt2, but not Akt1 or Akt3, results in an increase of PI3K-dependent invasion and metastasis of breast and ovarian cancer cells. 24 Increased Akt3 expression and loss of PTEN result in the development of melanoma, and Akt3 siRNA stimulates apoptosis and inhibits melanoma development. 25 Akt contributes to malignant transformation and/or tumor progression by acting on many substrates (for recent reviews see refs. 4, [26] [27] [28] ) including IKKa, Bad, caspase-9 and forkhead transcription factors. Intriguingly, Akt phosphorylates Mdm2, thereby stimulating the subsequent degradation of p53. Furthermore, Akt has a direct role in promoting cell-cycle progression by phosphorylating p21Cip1 and p27Kip1. Also, when growth factors are present, Akt can inhibit TSC1/2, eventually causing stimulation of mTOR, an important kinase that stimulates cell growth through promoting protein synthesis through ribosomal protein S6 kinase.
Because Akt is intimately involved in mediating many of the hallmarks of cancer, Akt has become a major anticancer drug target. 18, 19, 29, 30 Recently, we have discovered an Akt phosphorylation inhibitor, triciribine (TCN) and its active metabolite TCN-P, through screening the NCI Diversity Set. 31 This compound does not inhibit Akt kinase activity per se, but in whole cells prevents phosphorylation of Akt1, Akt2 or Akt3. 31 Furthermore, TCN does not inhibit PI3K, PDK1 and other protein kinases, but inhibits proliferation, induces apoptosis and inhibits tumor growth in animals much more potently in tumors that contain persistently hyperphosphorylated Akt, suggesting that TCN is a selective Akt activation inhibitor. 31 It is important to point out that TCN is a tricyclic nucleoside, 32 which, once inside cells, is phosphorylated to its monophosphate derivative, TCN-P, by adenosine kinase. TCN-P is the active metabolite of TCN, as in cells lacking adenosine kinase it is 5000-fold less active. 33 TCN-P is presently undergoing human clinical trials in patients whose tumors have high levels of phosphorylated Akt. 34 However, the mechanism by which TCN-P inhibits the phosphorylation of Akt is not known. In this study, using biochemical and cell biological studies, surface plasmon resonance (SPR) and nuclear magnetic resonance (NMR), we show that TCN-P, but not TCN, binds to the PH domain of Akt and prevents its recruitment to the plasma membrane and subsequent phosphorylation at T308 and S473. We also show that constitutively active Akt mutants, Akt1-T308D/ S473D and myr-Akt, but not Akt1-E17K, rescue cells from TCN-P effects suggesting that the ability of TCN-P to inhibit tumor cell growth is due to its ability to prevent Akt phosphorylation.
Results
TCN-P inhibits in vitro neither Akt kinase activity nor the phosphorylation of purified Akt by PDK1 and mTORC2. TCN-P inhibits the phosphorylation of Akt in whole cells, suppresses tumor growth and induces apoptosis selectively in tumors that have persistently hyperphosphorylated Akt compared with those that do not. 31 This prompted a clinical trial in a population of patients whose tumors contain persistently hyperphosphorylated Akt. 34 Critical to the clinical development of TCN-P as a targeted agent is to understand the biochemical mechanism by which it inhibits the phosphorylation of Akt. We have undertaken several biochemical, biophysical and cell biological studies to address this important question. First we determined whether in vitro TCN-P inhibits Akt kinase activity or the ability of PDK1 and mTOR to phosphorylate Akt at T308 and S473, respectively, the two phosphorylation sites required for full activation of Akt. TCN-P did not inhibit the ability of Akt1 to phosphorylate its substrate glycogen synthase kinase 3 (GSK3)-b in vitro (Figure 1a) . Furthermore, purified PDK1 and immunoprecipitated mTOR readily phosphorylated purified Akt1 at T308 and S473 in vitro, respectively, regardless of whether TCN-P was present in the reaction mixture or not (Figure 1b and 
TCN-P, but not TCN, binds to the PH domain of Akt as
shown by SPR. The results described in Figures 1 and 2 suggest that a possible mechanism by which TCN inhibits Akt phosphorylation in intact cells is that TCN-P binds to the PH domain of Akt, thereby preventing its recruitment to the plasma membrane. To explore this possibility, we carried out binding experiments using SPR and NMR with Akt-derived PH domain. First, we determined by SPR whether TCN-P and/or TCN bind the PH domain of Akt. Figure 3a shows a typical sensorgram obtained with six TCN-P concentrations (46 nM to 11.1 mM), indicating that TCN-P bound to the PH domain of Akt in a dose-dependent manner. TCN-P bound to the Akt PH domain with a k a of 366 (per Ms), a k d of 2.52 Â 10 À4 (per second) and a K D of 690 nM ( Figure 3a ). In contrast, TCN did not bind the Akt PH domain (Figure 3b ). Figure 3c shows the responses after a contact time of 300 s for TCN-P and TCN as a function of their concentration, further showing that TCN-P, but not TCN, binds to the Akt PH domain. To validate these results, we carried out several control experiments. Table 1 summarizes the kinetic data obtained with several compounds and the Akt-PH domain. As a positive control, we used Akt inhibitor VI, a peptide derived from the TCL1 oncoprotein that was reported to bind the PH domain of Akt, 35 and found in our experiments that it binds the Akt-derived PH domain with a K D of 1.4 mM (Table 1) . Furthermore, PIP3, the plasma membrane lipid that recruits Akt to the plasma membrane, bound the Akt-PH domain with a k a of 4251 (per Ms), a k d of 2.05 Â 10 À4 (per second) and a K D of 48 nM (Table 1) . Ligand-binding studies by NMR chemical shift mapping reveal that TCN-P, but not TCN, binds Akt-PH domain.
To further characterize the binding properties of TCN-P and TCN to the Akt PH domain, we conducted ligand-binding studies using NMR. Chemical shift mapping data suggest that Akt-PH domain residues in the PIP3-binding pocket 36, 37 were perturbed on complexation with TCN-P, but perturbation also extended outside this region (Figure 4a and b) , possibly due to some small conformational changes upon binding. For example, G16, I19, R23, R25 and I36 all show chemical shift perturbation. Conversely, no appreciable chemical shift perturbation could be observed with the compound TCN (Figure 4a and b) . This is consistent with the SPR results and suggests that the presence of the phosphate group is essential for binding (see more below).
Hence, on the basis of chemical shift mapping studies, we performed molecular docking studies to provide further possible binding poses of TCN-P in the PIP3-binding site of Akt PH domain. A possible binding mode for the compound was obtained using the program GOLD version 2.1 (CCDC Software Ltd., Cambridge, UK) and the structure of Akt PH domain (PDB code: 1H10). 36 The TCN-P-binding site was defined within a 15 Å radius around the residue K14, 36 located at the PIP3-binding site. A total 100 runs were performed and the conformation of TCN-P with the best GOLD score is shown in Figure 4c , along with the binding mode of inositol (1,3,4,5)-tetrakisphosphate (IP4), the well-accepted head group of PIP3 that binds to the Akt PH domain 36, 37 ( Figure 4d ). For comparison, Figure 4e and f shows spacefilling models and the interacting amino-acid residues for both TCN-P and PIP3. Although ultimately X-ray diffraction studies will be needed to further delineate the intermolecular contacts at the atomic level, the docking pose obtained further suggests that TCN-P partially mimics the binding interactions provided by PIP3. Indeed, in the docking models, the phosphate of TCN-P is positioned at the location of the D3 phosphate of PIP3 and is surrounded by the residues K14, R23, R25 and N53 (Figure 4e and f) . These are the same residues that have been shown to interact with the D3 phosphate of PIP3 in the crystal structure of Akt PH domain and PIP3. 36 Furthermore, the five-membered sugar ring of TCN-P (Figure 4c and e) can almost be superimposed to the six-membered ring of PIP3 (Figure 4d and f).
Constitutively active Akt1-T308D/S473D and myr-Akt1 but not Akt1-E17K rescue from TCN-mediated inhibition of Akt activation, loss of cell viability and induction of apoptosis. The results from Figures 1-4 show that TCN-P binds to the PH domain of Akt and inhibits its recruitment to the plasma membrane, and suggest this as a mechanism by which TCN treatment of cells inhibits Akt phosphorylation and subsequent activation. If this is the case, we reasoned that an Akt mutant that no longer requires recruitment to the plasma membrane and activation by phosphorylation would be resistant to TCN-P, and rescues cells from TCN-Pmediated inhibition of proliferation and induction of apoptosis. To evaluate this possibility, we stably expressed in COS-7 cells either Myc-tagged wild-type Akt1 or Myc-tagged Akt1-T308D/S473D (Akt1-DD), a constitutively active Akt mutant that does not require plasma membrane binding or phosphorylation at T308 and S473 for activation. Both wildtype Akt1-and Akt1-DD-, but not the vector-transfected cells, expressed the Myc-tagged Akt proteins (Figure 5a (Figure 5a , right panel). In addition to Akt1-DD, we used two other constitutively active mutants of Akt. The first is myristoylated Akt1 (myr-Akt1), which does not require its PH domain for plasma membrane recruitment. The other mutant of Akt is the naturally occurring, transforming mutant Akt1-E17K, which requires the PH domain for plasma membrane recruitment. As expected, in the absence of EGF, cells expressing wild-type Akt1 had much lower levels of phospho-Akt than those expressing either Akt1-E17K or myr-Akt1, whereas cells expressing Akt1-DD had no detectable phospho-Akt (Figure 5b ). Upon stimulation with EGF, wild-type phospho-Akt levels increased and TCN treatment decreased these wild-type phospho-Akt levels. TCN also inhibited the phospho-Akt levels in cells expressing Akt1-E17K, but to a lesser degree. In contrast, TCN had no . 36 The overall orientation is the same as that in (c). (e) Surface representation of the docking complex Akt/TCN-P and (f) of the complex Akt/IP4. In both panels, the overall surface of Akt was colored according to lipophilicity (blue, less lipophilic; brown, more lipophilic). The hydrogen bonds predicted to be formed between Akt and the compounds are shown as yellow dashed lines. The position of residues involved in the formation of hydrogen bonds is shown in white and yellow. In (e), the position of residues showing chemical shifting perturbation in (c) is also shown using the color code as in (c)
Mechanism of action of the Akt inhibitor TCN-P N Berndt et al effect on phospho-Akt levels in cells expressing myr-Akt1. Furthermore, TCN inhibited endogenous phospho-GSK3-b in cells expressing wild-type Akt1, but not Akt1-DD or myr-Akt1. TCN inhibited phospho-GSK3-b in Akt1-E17K expressing cells, but to a lesser degree (Figure 5b ). We next determined the effect of TCN treatment for 24 h on the proliferation of these same cells by MTT assay. Cells transfected with vector alone were not sensitive to TCN (Figure 5c ). Because these cells have virtually undetectable levels of phospho-Akt (Figure 5d ), this is in agreement with our previous report showing that human cancer cells low in phospho-Akt levels are less sensitive to TCN than those with high phospho-Akt levels. 31 Stable expression of wild-type Akt1 rendered these cells sensitive to TCN. However, both the constitutively and phospho-GSK3-b(S9) were examined by western blotting, with vinculin serving as loading control. The Myc blots show that the recombinant proteins were being expressed at comparable levels. (c) COS-7 cells expressing Akt1 constructs were exposed to TCN for 24 h and then subjected to MTT assay 41 to determine their proliferation/viability. The graph is representative of three independent experiments. (d) COS-7 cells have very low basal levels of phospho-Akt. To assess basal levels of S473 phosphorylation in Akt of COS-7 cells, we compared the phospho-Akt levels in COS-7 cells stably transfected with vector or wild-type Akt1, following exposure to vehicle (0.1% DMSO, lanes 1 and 6) or increasing concentrations of TCN for 24 h. Cells were lysed as described in Materials and Methods, and analyzed by western blotting with the indicated antibodies. (e) COS-7 cells expressing vector, wt-Akt1, Akt1-DD, Akt1-E17K or myr-Akt1 were exposed to TCN for 24 h and then lysed. Triplicate aliquots of these lysates were analyzed by caspase-3 assay as described in Materials and Methods. This was calculated, separately for each of the three cell types, by dividing the average fluorescence intensity at a given TCN concentration by the average fluorescence intensity in the absence of TCN. The graph is representative of two independent experiments active mutants, Akt1-DD and myr-Akt1, rescued these cells from TCN-mediated inhibition of viability, whereas cells expressing Akt1-E17K were sensitive toward TCN, but not as sensitive as those expressing wild-type Akt1. Thus, Akt1-DD and myr-Akt1 are resistant to TCN and rescue from TCN effects. Consistent with these results, TCN treatment of cells expressing vector, Akt1-DD or myr-Akt1 failed to induce any noticeable caspase-3 activity, whereas cells expressing wild-type Akt1 showed a 2-to 11-fold activation of caspase-3 in response to TCN. Furthermore, in cells expressing Akt1-E17K, TCN activated caspase-3 by up to fourfold (Figure 5e ). Taken together, these results suggest that TCN-induced apoptosis depends on its ability to prevent Akt phosphorylation.
Discussion
The PI3K/PTEN/Akt pathway is one of the most frequently deregulated pathways in human cancer. This justifies the need for potent and specific inhibitors capable of downregulating Akt. Targeting Akt directly would also be expected to neutralize malfunctions due to overexpression or activating mutations of PI3K and nonfunctional PTEN, which are often responsible for Akt hyperactivation. We have recently identified a compound, TCN, that has antitumor activity selectively in tumor cells that contain persistently hyperphosphorylated Akt compared with those tumors that do not. 31 Because TCN does not inhibit Akt kinase activity in vitro, but prevents the phosphorylation of Akt in intact cells, TCN is thought to function as an Akt activation inhibitor rather than an Akt inhibitor, but its precise mechanism of action remains to be determined. As Akt regulation is complex (see introduction), in theory several strategies exist to inhibit Akt, such as (1) direct inhibition of Akt enzyme activity, (2) inhibition of Akt phosphorylation, (3) activation of Akt dephosphorylation or (4) prevention of Akt translocation to the plasma membrane, which is a prerequisite for the critical phosphorylations at T308 and S473. In this article, we provide evidence that TCN functions primarily through the latter mechanism.
Using SPR and NMR (see Figures 3 and 4) , we have shown that TCN-P, which is known to be the active metabolite of TCN inside cells, 33 can directly bind to the PH domain of Akt1 or Akt2. In contrast, TCN did not bind, demonstrating that the phosphate group is important for binding. The fact that TCN-P, but not TCN, binds to the PH domain of Akt supports our proposed mechanism of TCN-P competing with PIP3 and preventing Akt membrane binding. This is consistent with previous reports showing that cells unable to convert TCN to TCN-P are highly resistant to TCN. 33 Furthermore, our NMR studies also showed that TCN-P, but not TCN, interacted with amino acids that are involved in PIP3 binding, which is in agreement with molecular docking studies suggesting that the Akt-PH domain PIP3-binding site can accommodate TCN-P. For example, TCN-P, but not TCN, caused chemical shifts perturbation in Akt-PH domain amino acids known to be involved in PIP3 binding. Furthermore, molecular docking shows that the phosphate group of TCN-P occupies the binding pocket of the D3 phosphate in PIP3 involving residues K14, R23, R25 and N53 of the Akt-PH domain. Finally, the sugar ring of TCN-P occupies the binding site of the six-membered ring of PIP3. Collectively, the results of SPR and NMR experiments, combined with computational docking studies, explain why TCN-P did not prevent the phosphorylation of Akt by either PDK1 or mTOR in vitro (Figure 1 ), but TCN prevented the translocation of Akt to the plasma membrane following EGF stimulation in intact starved cells (Figure 2 ). This is most likely due to TCN-P preventing PIP3 from recruiting Akt to the plasma membrane, possibly by either competing with PIP3 for binding to the Akt PH domain or binding to an adjacent pocket that induces conformational changes preventing PIP3 binding.
The behavior of the two mutants, Akt1-DD and myr-Akt1, supports this interpretation. Figure 5 shows that these forms of Akt1 do not depend on growth-factor-dependent phosphorylation for activation and suggests neither Akt1-DD nor myr-Akt1 depend on growth factor-dependent recruitment to the plasma membrane or on membrane-associated phosphorylation. Therefore, both Akt1-DD and myr-Akt1 are constitutively active. Interestingly, ectopic expression of wild-type Akt1 conferred TCN sensitivity to COS-7 cells (Figure 5c and e). This is consistent with previous data that showed that parental NIH 3T3 cells are resistant to TCN whereas Akt2-overexpressing NIH 3T3 cells are sensitive to TCN. 31 This is also consistent with the observation that human cancer cells with low phospho-Akt levels (OVCAR5, DU-145, T47D, Colo357, WM852) are much less sensitive than human cancer cells with high levels of phospho-Akt (OVCAR3, OVCAR8, PANC1, LNCaP, PC-3, MDA-MB-468, WM35). 31 In contrast, Akt1-DD was no longer phosphorylated at T308 or S473 and its ability to phosphorylate the Akt substrate GSK3-b was resistant to TCN. Similarly, in cells expressing myr-Akt1, TCN was unable to inhibit Akt1 phosphorylation at S473 or to inhibit phosphorylation of GSK3-b. In agreement with the failure of TCN to affect Akt phosphorylation and kinase activity, cells that express these constitutively active Akt mutants were resistant to TCN-induced loss of viability and apoptosis. These data support the notion that the mechanism by which TCN inhibits tumor survival and growth is by preventing the phosphorylation of Akt. Furthermore, cells expressing the transforming mutant Akt1-E17K were less sensitive to TCN-induced inhibition of Akt and were also less sensitive to TCN inhibition of proliferation and induction of apoptosis. A possible explanation for the reduced sensitivity of this mutant is that replacement of a negative with a positive charge (associated with the E-to-K mutation in position 17) is predicted to result in tighter binding of Akt1-E17K to the phospholipids of the plasma membrane. 22 Therefore, this would slightly reduce, but not abolish the ability of TCN to interfere with the function of Akt1-E17K.
In summary, our study data have delineated a mechanism of action for the anticancer drug and chemical probe TCN-P. This small molecule appears to function primarily by binding to the PH domain of Akt and preventing the recruitment of Akt to the cell membrane, where this protein is normally activated by phosphorylation. Our study results also support a mechanism of antitumor activity of TCN-P that involves inhibition of Akt phosphorylation, and suggest that in future TCN-P clinical trials, it would be important to evaluate the levels of phosphoAkt as a biomarker for TCN-P activity in patients whose tumors have high levels of phospho-Akt. EGF was purchased from Invitrogen. The caspase-3 substrate Ac-DEVD-AMC, Akt inhibitor X and Akt inhibitor VI, a 15 residue peptide derived from the oncogene TCL1, 35 were purchased from Calbiochem (San Diego, CA, USA). PIP3 was from Cayman Chemicals (Ann Arbor, MI, USA).
Cells and cell culture. MDA-MB-468 breast cancer cells, HEK-293T cells and COS-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and cells were maintained at 371C in a humidified atmosphere containing 5% CO 2 .
Generation of recombinant Akt constructs. The DNA sequence of the human Akt1 PH domain (coding for residues S2-S128, accession number: NP_005154.2) was PCR-amplified using the full-length Akt1 sequence (codonoptimized for the expression in E. coli and purchased from GeneArt, Regensburg, Germany) as a template. In the PCR reaction, the DNA oligomer ATCGCATATG GGATCCTCTGATGTTGCCATTGTTAAAGA was used as the 5 0 end primer with NdeI and BamHI restriction sites and the DNA oligomer GCTAGCGGCCG CTTAGCTCGGGCTACCGCTACG as the 3 0 end primer with an NotI restriction site. The PCR product was subcloned into the pET28a vector (Novagen, San Diego, CA, USA) through the BamHI and NotI site coding for a N-terminally His 6 -tagged Akt1 PH domain S2-S128 construct with a 24 residue spacer region (bold letters) between the His 6 tag and the PH domain: MGSSHHHHHHSSGLVPRGSHMA SMTGGQQMGRGS-S2-PH-S128.
E. coli BL21(DE3) cells were transformed with the pET28a-His 6 -spacer-PH(S2-S128) plasmid and grown at 371C in 4 liter Luria Bertani medium supplemented with 30 mg/ml kanamycin until the cell culture showed an OD 600 of 0.5-0.7. The expression of the His 6 -tagged PH-Akt1 construct was induced by adding 250 mM isopropyl-D-thiogalactopyranoside. Cells were further incubated at 22-251C for 16 h.
Cells were collected by centrifugation and lysed by resuspension in 0.1 M Na/K-phosphate buffer (pH 7.0), 300 mM NaCl, 10 mM imidazole, 0.5 mg/ml lysozyme, 0.01% Triton X-100. After 1 h incubation at 41C, cells were disrupted by sonication. Soluble protein was separated from cell debris and insoluble protein by centrifugation for 1 h at 53 000 Â g. The supernatant was loaded onto an Ni-NTA column (Qiagen, Valencia, CA, USA), and the His 6 -tagged PH-Akt1 was eluted using 10 volumes of a 10-250 mM imidazole gradient. The peak fractions eluting at imidazole concentrations between 170 and 220 mM consisted of almost pure His 6 -tagged PH-Akt1 (X98%). The fractions were pooled, and loaded onto a Superdex 200 gel filtration column (GE Healthcare, Princeton, NJ, USA) to remove misfolded aggregated protein. The His 6 -tagged PH-Akt1 was concentrated to approximately 20 mg/ml using appropriate Amicon centrifugal filter units (Millipore). The concentrated protein was aliquoted, shock frozen in liquid nitrogen and stored at À801C.
The phospho-mimicking constitutively active Myc-tagged Akt1-DD and the transforming mutant Akt1-E17K were generated using the pCMV-Tag3B vector and the QuikChange Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA, USA). As a template, we used human Myc-tagged wild-type Akt1 (accession number: NM_001014431.1). Myr-Akt1 was prepared as described previously. 38 The DNA sequences of the wild-type and mutant cDNAs encoding the recombinant constructs were validated by our Molecular Biology Core Facility and were found to be correct.
In vitro phosphorylation assays. The effect of TCN on the phosphorylation of Akt or the kinase activity of Akt was essentially determined in two ways: by using either purified recombinant proteins or lysates or proteins immunoprecipitated from cells transfected with recombinant Akt.
Nonradioactive in vitro Akt kinase assay was performed in the presence of 200 mM ATP with GSK-3b as a substrate according to the manufacturer's instructions (Cell Signaling), except that we used Myc antibody instead of immobilized Akt antibody to immunoprecipitate Akt.
To assess phosphorylation of Akt by PDK1, we incubated human recombinant inactive Akt1 (30 ng) with PDK1 (100 ng) in the presence of 200 mM ATP for the indicated time at 301C in a buffer consisting of 5 mM MOPS (pH 7.2), 2.5 mM b-glycerophosphate, 1 mM EGTA, 0.4 mM EDTA, 5 mM MgCl 2 and 0.05 mM DTT. The reaction was terminated by adding 8 ml of 4 Â SDS sample buffer to 30 ml of the reaction mixture and heating at 951C for 5 min. Samples were subjected to 10% SDS-PAGE. Phosphorylation at T308 and S473 was monitored by subsequent western blotting with the phosphorylation site-specific antibodies and developed using Chemiluminescence reagents (PerkinElmer, Boston, MA, USA).
For in vitro kinase assays following exposure of cells to TCN, we transfected cells with vector, myc-wt-Akt1, myc-Akt1-DD or myc-Akt1-E17K using LipofectAMINE-2000. COS-7 cells stably transfected with these Akt1 constructs were selected by G418 (Sigma). Myr-Akt1 was transiently transfected into COS-7 cells.
The phosphorylation of Akt at S473 was assayed with immunoprecipitated mTOR as described by Sarbassov et al. 39 with slight modifications. Briefly, 293T cells transfected with myc-tagged mTOR were lysed in lysis buffer containing 40 mM HEPES (pH 7.5), 120 mM NaCl, 0.3% CHAPS, 1 mM EDTA, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 and protease inhibitor cocktail. Lysate (1 mg) was precleared by incubating with 20 ml protein G Sepharose conjugated to preimmune IgG. The lysates were then incubated with 25 ml Protein G and mTOR antibody. Immune complexes were incubated for 4 h at 41C on a vibrating platform. Immunoprecipitates were washed four times with the above lysis buffer, followed by two washes with the mTOR kinase buffer (25 mM HEPES (pH 7.5), 100 mM potassium acetate, 1 mM MgCl 2 ). Immunoprecipitates were incubated in 30 ml of the mTOR kinase buffer containing 300 ng inactive Akt1 and 500 mM ATP at 371C. The reaction was stopped by the addition of 8 ml of 4 Â SDS sample buffer, and analysis of Akt phosphorylation by western blotting was performed as described above.
Immunofluorescence analyses of Akt1 membrane localization and phosphorylation. MDA-MB-468 cells growing on coverslips in six-well plates were transiently transfected with pCMV-Myc-wt-Akt1 by LipofectAMINE-2000 (Invitrogen) according to the manufacturer's instructions. At 48 h after transfection, cells were serum-starved overnight and treated with 20 mM TCN for 1 h and/or 100 ng/ml EGF for 15 min. Cells were washed three times with cold phosphatebuffered saline (PBS) and fixed in 4% formaldehyde for 30 min. Fixed cells were mounted onto glass slides with Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA, USA) containing DAPI (1.5 mg/ml) and stained with Myc antibody (1 mg/ml), followed by Alexa Fluor 594-conjugated secondary antibody (1 mg/ml). Fluorescence was observed using a Zeiss Axiovert Upright Fluorescent microscope (Göttingen, Germany) with a Â 60 oil-immersion lens. For each experiment, approximately 100 Akt1-expressing cells were scored to quantify membrane localization of Akt1. We scored as positive for Myc-Akt1 membrane localization those cells whose perimeter showed a brightly red stain that was distinctly set apart from the nuclear blue DAPI stain. Results are presented as percentage of membrane-positive cells per total Akt1-expressing cells. Each bar represents the mean of three experiments±S.D. To assess Akt phosphorylation at S473, we used Akt antibody and phospho-Akt(S473) (193H12) Alexa Fluor 488-conjugated secondary antibody, using similar procedures as described above.
Cell fractionation. Cytosol and membrane fractions were prepared as described by Fukuda et al. 40 Briefly, cells were suspended in hypotonic lysis buffer (25 mM Tris/HCl (pH 7.4), 5 mM EDTA, 1 mM dithiothreitol, 1 mM Na 3 VO 4 , 2.5 mM Na 4 P 2 O 7 and protease inhibitors) and disrupted by five passages through a 27-gauge needle. Large cell debris was pelleted by centrifugation at 2000 Â g for 5 min at 41C. The supernatants were centrifuged at 100 000 Â g for 20 min at 41C. The resulting supernatant (cytosol) was collected, and the pellet was washed once with hypotonic lysis buffer, then resuspended in hypotonic lysis buffer containing 1% Triton X-100. The lysate was again centrifuged at 100 000 Â g for 20 min at 41C, and the supernatant (membrane) was collected. The distribution of proteins in the cytosol and membrane fractions was analyzed by western blotting.
Surface plasmon resonance. The Biacore T100 instrument, the Series S sensor chips CM5 and NTA, the amine and thiol coupling kits, Biacore T100 Control and Evaluation software were purchased from GE Healthcare. The Akt inhibitor VI (reported K D for Akt1 PH domain ¼ 18 mM
35
) was used as a positive control.
